The goal of this observational study is to learn about the treatment effectiveness of physician's choice of chemotherapy and the immune checkpoint inhibitor (ICI)-based therapy in patients with relapsed/refractory ovarian clear cell carcinoma (OCCC), and compare the treatment response with the phase II, single-arm clinical trial INOVA to investigate the efficacy of combinational therapy of sintilimab plus bevacizumab. The main questions it aims to answer are: * What is the efficacy of physician's choice of chemotherapy in relapsed/refractory OCCC patients in the real world? * Is ICI-based therapy more effective than physician's choice of chemotherapy in real-world for relapsed/refractory OCCC patients? * Dose the combinational regimens of sintilimab plus bevacizumab in Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA) trial more effective than physician's choice of chemotherapy? Participants will be respectively retrieved and extracted de-identified, longitudinal electronic health records (EHR)-derived data.
Study Type
OBSERVATIONAL
Enrollment
150
physician's choice of chemotherapy for relapsed/refractory ovarian clear cell carcinoma
immune checkpoint inhibitor based therapy for relapsed/refractory ovarian clear cell carcinoma
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
RECRUITINGtumor response rate
The tumor responses to treatment were evaluated by an independent central investigator according to RECIST version 1.1
Time frame: through study completion, an average of 1 year
progression-free survival (PFS)
the time from therapy initiation to the first documented progression or death from any cause, whichever occurred first
Time frame: through study completion, an average of 1 year
time to response (TTR)
the time from therapy initiation to the first documented complete response or partial response
Time frame: through study completion, an average of 3 months
duration of response (DOR)
the time from the first documented response to disease progression or death, whichever occurs first
Time frame: through study completion, an average of 1 year
disease control rate (DCR)
the proportion of patients with complete response, partial response, and stable disease
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.